Aligos Therapeutics, Inc. (ALGS) Reports Q2 Loss, Misses Revenue Estimates

Company Performance - Aligos Therapeutics reported a quarterly loss of $1.53 per share, which was better than the Zacks Consensus Estimate of a loss of $2.35, representing an earnings surprise of +34.89% [1] - The company posted revenues of $0.97 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 3.5%, and down from $1.06 million a year ago [2] - Over the last four quarters, Aligos has surpassed consensus EPS estimates two times and topped revenue estimates only once [2] Stock Movement and Outlook - Aligos Therapeutics shares have declined approximately 80.2% since the beginning of the year, contrasting with the S&P 500's gain of 7.1% [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the next quarter is -$2.48 on $1 million in revenues, and for the current fiscal year, it is -$9.71 on $2.16 million in revenues [7] Industry Context - The Medical - Biomedical and Genetics industry, to which Aligos belongs, is currently ranked in the bottom 42% of over 250 Zacks industries, indicating potential challenges for stock performance [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Aligos's stock performance [5][6]